Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028, The ...

The healthcare giant is dealing with the fast-approaching patent cliff for its most important product, cancer medicine ...

Merck’s problems in China seem to be getting worse, raising questions about the company’s growth. Trouble with sales of Merck ...

Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

However, Keytruda patents are set to lose exclusivity post 2028. Merck is working on different strategies to drive Keytruda's long-term growth. These include innovative immuno-oncology ...

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...

Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...

Merck's Keytruda should continue growing its sales until it faces a patent cliff in 2028. The company is developing other medicines to deal with mounting competition. Merck is also a solid choice ...

The healthcare giant is dealing with the fast-approaching patent cliff for its most important product, cancer medicine Keytruda. Further, even beyond Keytruda's upcoming loss of patent exclusivity ...